Work

From Diabetes to Dermatology: The Role of Teneligliptin in Bullous Pemphigoid Development

Year: 2025

Type: article

Abstract: Bullous pemphigoid (BP) is an autoimmune blistering disease that especially presents in elderly patients, but recently, its incidence has increased in patients treated with inhibitors of dipeptidyl peptidase-4 (DPP-4), among which teneligliptin is widely prescribed as an antidiabetic drug for the treatment of type 2 diabetes mellitus (T2DM). Recent studies describe the association of teneligliptin with the onset of BP, hypothesizing that DPP-4 inhibition could induce immune dysregulation able to trigger autoimmune responses against skin antigens BP180 and BP230. This mini-review discusses the immunomodulatory effects of teneligliptin, immune responses, and chronic inflammation associated with diabetes that predispose patients to BP. It also discusses the clinical implications, such as monitoring for BP in T2DM patients on teneligliptin therapy. Elucidation of this relationship may help in optimizing management strategies by highlighting discontinuation or alternative therapies in the case of a high risk of development of BP.

Source: Current Diabetes Reviews

DOI: 10.2174/0115733998370106250610103519

Authors: Md. Sadique Hussain, Gurusha Bahl, Yumna Khan, Ajay Singh Bisht, Gaurav Gupta

Institutions: Uttaranchal University, The University of Agriculture, Peshawar, Shri Guru Ram Rai University, Ajman University, Chitkara University

Language: English

Topic: Autoimmune Bullous Skin Diseases

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4415274695

FWCI: 0.598

Cites: 66

Cited by: 1

Related to: